Company intelligence / Profile preview
Huabo Biopharm
Shanghai, Shanghai, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Huabo Biopharm has multiple biologic programs in the clinic, notably HB0025 (first-in-class bispecific antibody targeting PD-L1/VEGF, in Phase I for solid tumors in US/China), HB0034 (IL-36R antagonist in Phase I for autoimmune diseases), and late-stage (Phase III) IL-17 antibody for psoriasis, with several other antibodies and fusion proteins in mid/early-stage clinical trials[1][2][4][7][8].
- Therapeutic areas
- ImmunologyNephrologyRheumatologyOphthalmologyGastroenterologyDermatologyPulmonologyOncology
- Modalities
- Monoclonal antibodyBispecific antibodyFusion proteinAntibody-drug conjugateRecombinant proteinBiosimilar
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Shanghai Junshi Biosciences (Junshi acquired HOT-1010 from Huaota)Zhejiang Huahai Biopharmaceuticals (Clinical manufacturing)Korea Eutilex Co., Ltd. (Strategic collaboration)US Oncobiologics Inc. (Strategic collaboration)
Beyond the preview
Go deeper on Huabo Biopharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Huabo Biopharm.